Today, more than ever, finding less invasive ways to underwrite impairments efficiently and effectively is of vital importance. New research on reliable mortality and morbidity indicators for diabetes offers important clues.
While the medical impact of COVID-19 on survivors is not yet fully understood, history from past outbreaks can impart important lessons. Read more.
Explore how diagnostics companies are modifying operations to help in the fight against the virus in OTR.
While there’s no cure for polycystic kidney disease, genetic screening could provide a path forward. Explore questions and underwriting considerations in OTR.
Russell Scott of Munich Re suggests emerging aerosol biopsy technology may allow for a speedier, less costly and non-invasive pulmonary evaluation. Learn more in OTR.
Get a complete view in OTR from Dr. Nico Van Zyl of Hannover Re, including a comparison with traditional cancer therapies. Read more in OTR.
Innovation does not happen with pilots, but through partnerships. That was the message from presenters at CIRC 2019 Platform Revolution. Get the highlights in OTR.